{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T08:43:43Z","timestamp":1697705023976},"reference-count":21,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,1,8]],"date-time":"2010-01-08T00:00:00Z","timestamp":1262908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Delayed initiation of granulocyte colony stimulating factor (G\u2010CSF) after high\u2010dose chemotherapy and autologous bone marrow or peripheral blood stem cell (APBSCT) in adult patients does not affect time to neutrophil or platelet engraftment, duration of fever, incidence of bacteremia, duration of non\u2010prophylactic antibiotic therapy, and length of hospitalization when compared to early initiation. This study compares the effect of delayed (day +6) versus early (day +1) administration of G\u2010CSF in pediatric patients on time to neutrophil engraftment (TNE), duration and cost of G\u2010CSF therapy, incidence of blood stream infections, duration of febrile\u2013neutropenia, duration of non\u2010prophylactic antibiotic therapy, and duration of hospitalization due to febrile\u2013neutropenia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a retrospective review of 65 patients who engrafted after receiving APBSCT and G\u2010CSF between 1993 and 2006. They were divided into the delayed group (day +6) (n\u2009=\u200946) and the early group (day +1) (n\u2009=\u200919).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median ages were 4.7 and 5.3 years in the early and delayed groups, respectively. There was no significant difference in TNE (<jats:italic>P<\/jats:italic>\u2009=\u20090.06) between the two groups. The duration of G\u2010CSF administration was significantly less in the delayed group (<jats:italic>P<\/jats:italic>\u2009=\u20090.003). No significant differences were observed in the duration of neutropenia, time to platelet engraftment, the incidence of blood stream infections, and duration of fevers. Duration of hospitalization due to febrile\u2013neutropenia was significantly lower in the delayed group (<jats:italic>P<\/jats:italic>\u2009=\u20090.01). Significant cost savings were observed by delaying G\u2010CSF administration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Delayed administration of G\u2010CSF after APBSCT in children has no adverse effect on TNE or other clinical outcomes when compared to early administration and may incur substantial cost savings. Pediatr Blood Cancer 2010;54:728\u2013733. \u00a9 2009 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.22394","type":"journal-article","created":{"date-parts":[[2010,1,8]],"date-time":"2010-01-08T23:19:35Z","timestamp":1262992775000},"page":"728-733","source":"Crossref","is-referenced-by-count":3,"title":["Delayed administration of filgrastim (G\u2010CSF) following autologous peripheral blood stem cell transplantation (APBSCT) in pediatric patients does not change time to neutrophil engraftment and reduces use of G\u2010CSF"],"prefix":"10.1002","volume":"54","author":[{"given":"Vinita","family":"Pai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soledad A.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Laudick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Rosselet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Termuhlen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,3,4]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.9.1288"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19881201)62:11<2445::AID-CNCR2820621133>3.0.CO;2-I"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.6.1323"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.4.935"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.4703274.x"},{"key":"e_1_2_5_7_2","first-page":"271","article-title":"Effect of granulocyte colony\u2010stimulating factor on hematopoietic recovery after peripheral blood progenitor cell transplantation","volume":"13","author":"Shimazaki C","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.451"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701104"},{"key":"e_1_2_5_10_2","first-page":"4040","article-title":"Marginal benefit\/disadvantage of granulocyte colony\u2010stimulating factor therapy after autologous blood stem cell transplantation in children: Results of a prospective randomized trial. The Japanese Cooperative Study Group of PBSCT","volume":"92","author":"Kawano Y","year":"1998","journal-title":"Blood"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb06744.x"},{"key":"e_1_2_5_12_2","first-page":"533","article-title":"Administration of G\u2010CSF can be delayed after transplantation of autologous G\u2010CSF\u2010primed blood stem cells: A randomized study","volume":"17","author":"Faucher C","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700947"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701100"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701469"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-200102000-00003"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705097"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703079"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703538"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701203"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703539"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4451"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.22394","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.22394","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.22394","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:30:25Z","timestamp":1697675425000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.22394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,4]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1002\/pbc.22394"],"URL":"https:\/\/doi.org\/10.1002\/pbc.22394","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,4]]}}}